Nedisertib (Standard)

• Description:

  Nedisertib (Standard) is the analytical standard of Nedisertib (HY-101570) . This product is intended for research and analytical applications. Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity[1][2][3].

• Target:

  BCRP; DNA-PK; Reference Standards

• Related Pathways:

  Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Others; PI3K/Akt/mTOR

• Field of Research:

  Cancer

• Smiles:

  FC1=CC(Cl)=C([C@@H](C2=CC=C(N=N2)OC)O)C=C1C3=NC=NC4=C3C=CC(N5CCOCC5)=C4

• Molecular Formula:

  C24H21ClFN5O3

• Molecular Weight:

  481.91

• References & Citations:

  [1]L. Damstrup, et al. M3814, a DNA-dependent Protein Kinase Inhibitor (DNA-PKi), Potentiates the Effect of Ionizing Radiation (IR) in Xenotransplanted Tumors in Nude Mice. IJROBP. 2016; 94, 940-941.|[2]Thomas Fuchss, et al. Arylchinazoline. WO2014183850A1. 2014-11-20.|[3]Wu ZX, et al. M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. Front Oncol. 2020 May 12;10:674.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference Standards

• CAS Number:

  [1637542-33-6]